CannabisNewsBreaks

TuesdayMar 12, 2024 2:17 pm

CannabisNewsBreaks — Zoned Properties Inc. (ZDPY) Chooses IBN as Corporate Communications Partner

Zoned Properties (OTCQB: ZDPY), a technology-driven property investment company focused on acquiring value-add real estate within the regulated cannabis industry, is partnering with IBN, a multifaceted financial news and publishing company for private and public entities. According to the announcement, IBN will assist Zoned Properties with its corporate communications initiatives and help strengthen awareness of the company. Zoned Properties is focused on innovating in the real-estate development space, and is working to redefining the way people invest in commercial real estate. Zoned Properties offers a proprietary national ecosystem of real estate services, including a commercial real estate brokerage and a…

Continue Reading

FridayMar 08, 2024 2:56 pm

CannabisNewsBreaks – Astrotech Corporation’s (NASDAQ: ASTC) Subsidiary Tapping into Fast-Growing Opportunity

Astrotech (NASDAQ: ASTC), a science and technology company focused on commercializing its innovative platform mass spectrometry technology through its wholly owned subsidiaries, recently released financial results for Q2 2024. “The company recorded a 512% jump in its year-to-date (‘YTD’) revenue to $1,540,000 from $301,000 in the comparative period a year before. Astrotech attributed this growth primarily to two significant purchase orders for the TRACER 1000(TM) explosive trace detectors (‘ETDs’) to customers in Romania, which the company, through 1st Detect Corp., successfully delivered on. The subsidiary 1st Detect develops, manufactures and sells mass-spectrometer-based trace detectors – including the TRACER 1000(TM), the…

Continue Reading

ThursdayMar 07, 2024 2:03 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Hires CRO for Second DehydraTECH-Powered GLP-1 Human Pilot Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced it has hired a contract research organization (“CRO”) to perform the company’s second DehydraTECH-powered glucagon-like peptide 1 (“GLP-1”) human pilot study #2. According to the announcement, the study will be a randomized, crossover, placebo-controlled investigation that will compare three formulations, each at a 7 mg semaglutide dose: a positive control Rybelsus(R) swallowed tablet; DehydraTECH-semaglutide swallowed capsules; and, for the first time ever, an in-mouth dissolvable DehydraTECH-semaglutide oral tablet. “DehydraTECH has previously shown an ability to improve delivery of certain drugs destined for the bloodstream, through the…

Continue Reading

WednesdayMar 06, 2024 1:36 pm

CannabisNewsBreaks – Software Effective Solutions Corp. (SFWJ) Expands Portfolio, Marking Major Step Toward World-Leading Integration

Software Effective Solutions (OTC: SFWJ) (d/b/a MedCana) today announced the successful acquisition of two additional companies, expanding its portfolio to nine innovative enterprises. According to the announcement, the strategic expansion includes a company with a critical cannabis genetics license and another with comprehensive licenses to produce, process and export cannabis products. “These acquisitions represent a monumental step towards our vision of becoming a world-leading integrated cannabis company,” said Jose Gabriel Diaz, CEO of MedCana. “With seven cannabis producing companies, one agriculture technology and infrastructure company, and one software company under our belt, MedCana is exceptionally positioned to innovate, produce and…

Continue Reading

TuesdayMar 05, 2024 3:27 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) to Commence Diabetes and Weight Loss Animal Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced details for an eight-week animal study, WEIGHT-A24-1, to examine diabetes and weight loss effects of DehydraTECH-processed glucagon-like peptide 1 (“GLP-1”) drugs and DehydraTECH-processed cannabidiol, alone and in combination. The contract for the study was awarded to a third-party, Health Canada-licensed research laboratory. Manufacturing of the compositions for the first eight of the 12 study arms has been completed, and those arms will commence as soon as possible at the testing laboratory, expected to begin within 45 days. Each arm of the study will be dosed for…

Continue Reading

TuesdayMar 05, 2024 2:01 pm

CannabisNewsBreaks – Software Effective Solutions Corp. (SFWJ) Ideally Poised Amid Growing Evidence of Cannabis’ Benefits and Safety

Software Effective Solutions (OTC: SFWJ) (d/b/a MedCana), a global infrastructure and holding company in the cannabis industry, is paying close attention to growing data showing the power of cannabis. “One recent study, conducted by postdoctoral research fellow Thomas Arkell, a PhD at Swinburne University of Technology in Melbourne, Australia, suggests that medical cannabis treatment may be associated with improvements in health-related quality of life among patients with a range of health conditions. The results of the study were published earlier this year by JAMA Network Open… This is just one of innumerable studies focused on cannabis… ‘Based on evidence currently…

Continue Reading

TuesdayMar 05, 2024 1:36 pm

CannabisNewsBreaks – Zoned Properties Inc. (ZDPY) Marks Pivotal Step in Scaling D2C Real Estate Portfolio

Zoned Properties (OTCQB: ZDPY), a technology driven property investment company for emerging and highly regulated industries, including legalized cannabis, today announced that it has listed its cultivation property in Chino Valley, Arizona (the “Chino Valley Property”) for sale at a purchase price of $16 million. The potential transaction marks a significant development in the company’s strategic real estate portfolio optimization. “As part of our ongoing strategic review to enhance shareholder value, we are very pleased to announce our intention to sell our Chino Valley Property. The Chino Valley Property, which we now consider a non-core asset to our investment strategy,…

Continue Reading

MondayMar 04, 2024 1:08 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Weight-Loss Results in Animal Study, Begins Eight-Week Follow-Up Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, is reporting glucose reduction and weight-loss results in a testing of its wholly owned and patented DehydraTECH-CBD formulation. According to the announcement, when administered to rodents in an eight-week study, DehydraTech-CBD resulted in weight loss of 7% and a reduction of 19.9% (p<0.05) in blood glucose. As a result, Lexaria has now signed contracts to begin a large, multiweek animal study that will substantially progress its DehydraTECH-GLP-1 and DehydraTECH-CBD weight-loss investigations. In addition, the announcement also noted that the company had published results of a human study, which showed that a single…

Continue Reading

FridayMar 01, 2024 3:45 pm

CannabisNewsBreaks – Astrotech Corporation’s (NASDAQ: ASTC) Breakthrough TRACER 1000(TM) Designed to Outperform Currently Used IMS Detectors

Astrotech (NASDAQ: ASTC) is a mass spectrometry company that, through its wholly owned subsidiary 1st Detect, has developed and rolled out the breakthrough TRACER 1000(TM) Explosive Trace Detector (“ETD”). “The world’s first mass spectrometry-based ETD certified by the European Civil Aviation Conference (‘ECAC’), the TRACER 1000(TM) is designed to outperform the ETDs currently used at aviation checkpoints as well as borders, cargo facilities and other secured points around the world. It is powered by the Astrotech Mass Spectrometer (‘AMS’) Technology that is inexpensive, smaller and easier to use when compared to traditional mass spectrometers. The AMS Technology works under ultra-high…

Continue Reading

FridayMar 01, 2024 12:16 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Cleared to Commence HYPER-H23-1 Clinical Trial

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that the U.S. Food and Drug Administration (“FDA”) has confirmed the effectiveness of the company’s investigational new drug (“IND”) application thereby clearing Lexaria to conduct its planned U.S. Phase 1b hypertension clinical trial HYPER-H23-1 utilizing DehydraTECH-CBD. According to the announcement, the company is pleased to have complied with the FDA’s rules and procedures for clearance to perform this important registrational trial. The company will further announce when it is ready to begin the study, subject to certain conditions, including raising sufficient funding. “This is a significant…

Continue Reading